Cite
HARVARD Citation
Colombel, J. et al. (n.d.). DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD). Journal of Crohn's and colitis. pp. i161-i162. [Online].